sinij shares a news release from the Utah Department of Commerce: The state of Utah, through the Utah Department of Commerce's Office of Artificial Intelligence Policy, today announced a first-of-its-kind partnership with Doctronic, the AI-native health platform, to give patients with chronic conditions a faster, automated way to renew medications. This agreement marks the first state-approved program in the country that allows an AI system to legally participate in medical decision-making for prescription renewals, an emerging model that could reshape access to care and ultimately improve care outcomes. Politico provides additional context in its reporting: In data shared with Utah regulators, Doctronic compared its AI system with human clinicians across 500 urgent care cases. The results showed the AI's treatment plan matched the physicians' 99.2 percent of the time, according to the company. "The AI is actually better than doctors at doing this," said Dr. Adam Oskowitz, Doctronic co-founder and an associate professor of surgery at the University of California San Francisco. "When you go see a doctor, it's not going to do all the checks that the AI is doing." Oskowitz said the AI is designed to err on the side of safety, automatically escalating cases to a physician if there's any uncertainty. Human doctors will also review the first 250 prescriptions issued in each medication class to validate the AI's performance. Once that threshold is met, subsequent renewals in that class will be handled autonomously. The company has also secured a one-of-a-kind malpractice insurance policy covering an AI system, which means the system is insured and held to the same level of responsibility as a doctor would be. Doctronic also runs a nationwide telehealth practice that directs patients to doctors after an AI consultation. In Utah, patients who use the system will visit a webpage that verifies they are physically in the state. Then the system will pull the patient's prescription history and offer a list of medications eligible for renewal. The AI walks the patient through the same clinical questions a physician would ask to determine whether a refill is appropriate. If the system clears the renewal, the prescription is sent directly to a pharmacy. The program is limited to 190 commonly prescribed medications. Some medications -- including pain management and ADHD drugs as well as injectables -- are excluded for safety reasons.

Read more of this story at Slashdot.

Scientists at Melbourne's Peter Doherty Institute for Infection and Immunity are working on a Crispr-based treatment -- delivered as a nasal spray or injection -- that could stop influenza infections by targeting the virus's RNA and disrupting its ability to replicate inside human cells. The approach uses the Cas13 enzyme, a lesser-known cousin of the DNA-cutting Cas9, which can be engineered to seek out conserved regions of influenza's genetic code that are found in virtually all flu strains and are crucial to the virus's survival. The delivery mechanism would use lipid nanoparticles to ferry two molecular instructions to flu-infected cells in the respiratory tract: an mRNA that tells cells to produce Cas13 and a guide RNA that directs the enzyme to specific parts of the influenza virus's code. Cas13 then cuts the viral RNA and effectively stops the infection at the genetic level, Sharon Lewin, the infectious diseases physician leading the project, told Wired. Early safety testing at Harvard's Wyss Institute used a "lung on a chip" model to examine whether human cells producing Cas13 could fight off flu strains including H1N1 and H3N2. The institute's founding director Donald Ingber says the studies showed no off-target effects.

Read more of this story at Slashdot.

An anonymous reader shared this report from the Independent: Candida auris, a type of invasive yeast that can cause deadly infections in people with weakened immune systems, has infected at least 7,000 people [in 2025] across 27 U.S. states, according to data from the Centers for Disease Control and Prevention. The fungus, which can spread easily in healthcare settings such as hospitals and nursing homes, is gaining virulence and spreading at an "alarming" rate, the CDC says. Some strains of the fungus are particularly troublesome — and even considered a superbug — because they're resistant to all types of antibiotics used to treat fungal infections, The Hill reports. While healthy people may be able to fight off the infection on their own, the fungus can be deadly, especially in healthcare settings, where it can quickly spread amongst a vulnerable population. "If you get infected with this pathogen that's resistant to any treatment, there's no treatment we can give you to help combat it. You're all on your own," Melissa Nolan, an assistant professor of epidemiology and biostatistics at the University of South Carolina, told Nexstar... A recent study found that Candida auris is gaining virulence and spreading rapidly, not just in the U.S., but also globally. Candida auris has already been found in at least 61 countries on six continents. Some context from Newsweek: There are strategies available to combat Candida auris infection. While the superbug can develop ways to evade the immune response, vaccination and treatment strategies are possible, but researchers would like them to be strengthened. Four classes of antifungal drugs are currently available, with varying degrees of efficacy, and three new drugs are currently in trials or at newly approved stages

Read more of this story at Slashdot.

The Wall Street Journal reports that a growing number of tech startups are stocking offices with free nicotine pouches as founders and employees chase sharper focus and stamina in hyper-competitive AI-era work environments. The Wall Street Journal reports: Earlier this year, two nicotine startups -- Lucy Nicotine and Sesh -- made branded vending machines filled with flavored products for analytics company Palantir Technologies. Both machines are in the company's Washington, D.C., offices. The pouches are free for employees and guests over the age of 21, a spokeswoman for Palantir said. Palantir pays to stock the nicotine products. Alex Cohen, a startup founder based in Austin, Texas, said he was first exposed to nicotine pouches in the workplace after seeing tins of Zyns on the desks of his software engineers. His company, Hello Patient, makes AI-powered healthcare-communication software. "They were very productive, so I thought maybe there's something here," he said. Those engineers soon asked him if he could buy it for the office. Cohen said he initially bought the nicotine pouches as a joke for social media. He posted a picture of a drawer in his startup's office filled with nicotine pouches made by different brands with the caption, "We're hiring." "Then, I accidentally got addicted," said Cohen. He said he uses around two to three pouches a day. His go-to flavors are mango or minty. Cohen said he has attention-deficit/hyperactivity disorder, or ADHD, and he has found that the pouches can provide a quick productivity boost. "It helps with reining in my focus because it is a stimulant," he said. Today, Hello Patient has a nicotine-pouch fridge in its office kitchen.

Read more of this story at Slashdot.

A study by a Singapore government agency has found that children exposed to high levels of screen time before age two showed brain development changes linked to slower decision-making and higher anxiety in adolescence, adding to concerns about early digital exposure. From a report: The study was conducted by a team within the country's Agency for Science, Technology and Research and the National University of Singapore, and published in The Lancet's eBioMedicine open access journal. It tracked 168 children for more than a decade, and conducted brain scans on them at three time points. Heavier screen exposure among very young children was associated with "accelerated maturation of brain networks" responsible for vision and cognitive control, the study found. The researchers suggested this may have been the result of "intense sensory stimulation that screens provide." They found that screen time measured at ages three and four, however, did not show the same effects. Those children with "altered brain networks" took longer to make decisions when they were 8.5, and also had higher anxiety symptoms at age 13, the study said.

Read more of this story at Slashdot.

schwit1 shares a report from CBS News: perm from a donor who unknowingly carried a cancer-causing gene has been used to conceive nearly 200 babies across Europe, an investigation by 14 European public service broadcasters, including CBS News' partner network BBC News, has revealed. Some children conceived using the sperm have already died from cancer, and the vast majority of those who inherited the gene will develop cancer in their lifetimes, geneticists said. The man carrying the gene passed screening checks before he became a donor at the European Sperm Bank when he was a student in 2005. His sperm has been used by women trying to conceive for 17 years across multiple countries. The cancer-causing mutation occurred in the donor's TP53 gene -- which prevents cells in the body from turning cancerous -- before his birth, according to the investigation. It causes Li Fraumeni syndrome, which gives affected people a 90% chance of developing cancers, particularly during childhood, as well as breast cancer in later life. Up to 20% of the donor's sperm contained the mutated TP53 gene. Any children conceived with affected sperm will have the dangerous mutation in every cell of their body. The affected donor sperm was discovered when doctors seeing children with cancers linked to sperm donation raised concerns at this year's European Society of Human Genetics. At the time, 23 children with the genetic mutation had been discovered, out of 67 children linked to the donor. Ten of those children with the mutation had already been diagnosed with cancer. Freedom of Information requests submitted by journalists across multiple countries revealed at least 197 children were affected, though it is not known how many inherited the genetic mutation. More affected children could be discovered as more data becomes available.

Read more of this story at Slashdot.

In February, a six-month-old baby named KJ Muldoon became the first person ever to receive a CRISPR gene-editing treatment customized specifically for his unique genetic mutation, a milestone that researchers say marks a turning point in how medicine might approach the thousands of rare diseases that collectively affect 30 million Americans. Muldoon was born with a type of urea-cycle disorder that gives patients roughly a 50% chance of surviving infancy and typically requires a liver transplant; he is now a healthy 1-year-old who recently took his first steps. The treatment's significance extends beyond one child. Scientists at UC Berkeley's Innovative Genomics Institute and the Children's Hospital of Philadelphia are now planning clinical trials that would use Muldoon's therapy as a template, tweaking the molecular "address" in the CRISPR system to target different mutations in other children with urea-cycle disorders. Last month, FDA officials Marty Makary and Vinay Prasad announced a new drug pathway designed to accelerate approvals for such personalized treatments -- a framework inspired in large part by Muldoon's case. Current gene-editing delivery mechanisms limit treatments to disorders in the blood and liver. Many families will still go without bespoke therapies.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the Guardian: The journal Regulatory Toxicology and Pharmacology has formally retracted a sweeping scientific paper published in 2000 that became a key defense for Monsanto's claim that Roundup herbicide and its active ingredient glyphosate don't cause cancer. Martin van den Berg, the journal's editor in chief, said in a note accompanying the retraction that he had taken the step because of "serious ethical concerns regarding the independence and accountability of the authors of this article and the academic integrity of the carcinogenicity studies presented." The paper, titled Safety Evaluation and Risk Assessment of the Herbicide Roundup and Its Active Ingredient, Glyphosate, for Humans, concluded that Monsanto's glyphosate-based weed killers posed no health risks to humans -- no cancer risks, no reproductive risks, no adverse effects on development of endocrine systems in people or animals. Regulators around the world have cited the paper as evidence of the safety of glyphosate herbicides, including the Environmental Protection Agency (EPA) in this assessment (PDF). [...] In explaining the decision to retract the 25-year-old research paper, Van den Berg wrote: "Concerns were raised regarding the authorship of this paper, validity of the research findings in the context of misrepresentation of the contributions by the authors and the study sponsor and potential conflicts of interest of the authors." He noted that the paper's conclusions regarding the carcinogenicity of glyphosate were solely based on unpublished studies from Monsanto, ignoring other outside, published research. "The retraction of this study is a long time coming," said Brent Wisner, one of the lead lawyers in the Roundup litigation and a key player in getting the internal documents revealed to the public. Wisner said the study was the "quintessential example of how companies like Monsanto could fundamentally undermine the peer-review process through ghostwriting, cherrypicking unpublished studies, and biased interpretations." "This garbage ghostwritten study finally got the fate it deserved,â Wisner added. "Hopefully, journals will now be more vigilant in protecting the impartiality of science on which so many people depend."

Read more of this story at Slashdot.

Washington Post columnist Dana Milbank calls himself "a highly creative hypochondriac" — who just paid for an expensive MRI scan to locate abnormal spots as tiny as 2 millimeters. He discusses the pros and cons of its "diffusion-weighted imaging" technology combined with the pattern recognition of AI, which theoretically "has the potential to save our lives by revealing budding cancers, silent aneurysms and other hidden would-be killers before they become deadly. " But the scans cost $2,500 a pop and insurance won't pay. Worse, for every cancer these MRIs find, they produce a slightly greater number of false positives that require a biopsy, with the potential for infection and bleeding and emotional distress. Even when the scans don't produce a false positive, they almost always come up with some vague and disconcerting abnormality.... Will we feel better after viewing our insides? Or will we become anxious about things we hadn't even thought to worry about? Part of living has always been in the mystery, in not knowing what tomorrow will bring. Now, because of sophisticated imaging, genome sequencing and other revolutionary screening tools, we can have predictability, or at least the illusion of it. But do we want that? The American College of Radiology says we do not. Its still-current 2023 statement says there is not "sufficient evidence" to recommend full-body screening, cautioning that the scan could lead to needless testing and expense. But David Larson, chair of ACR's Commission on Quality and Safety, told me that could change as more data comes in. "When people ask me, 'Would you recommend it?' I would say it depends on your tolerance for ambiguity," he said, giving the example of somebody found to have a borderline aortic aneurysm who is advised to wait and monitor it. If "that won't keep you up at night, then I wouldn't necessarily recommend against it...." About 1 in 20 gets that dreaded call. A study Prenuvo presented earlier this year of 1,011 participants found that 4.9 percent of scans required a follow-up biopsy. Of those, 2.2 percent were actually cancer, and the other 2.7 percent were false positives. Of the 22 cancers the scans caught, 86 percent of patients had no specific symptoms. But if finding something truly awful is rare, finding something abnormal is almost guaranteed. [Vikash Modi, Prenuvo's senior medical director of preventative medicine] said only 1 in 20 scans come back completely clean. The vast majority of patients wind up in the ambiguous realm where something may look suspicious but doesn't require urgent follow-up. He opted for the cheaper $1,000 torso scan, which the senior medical director calls "our bread-and-butter area," since 17 of the 22 cancers detected in one Prenuvo study were in that area and is where they often find cancers that wouldn't be discovered until they were incurable like "that scary pancreatic stuff...." Milbank's scan found 12 "abnormalities" included "a 2.5 mm pulmonary nodule in the right lower lobe" and "a 4.6 mm intraductal papillary mucinous neoplasm in the pancreatic tail" — but with 10 abnormalities labeled "minor" (and six being musculoskeletal wear-and-tear problems "I already knew about from the usual aches and pains".) Even the two "moderate" findings didn't sound that grim when I read on. The "indeterminant lesion" in my lung requires no follow-up, while the thing in my pancreas is "low-risk."... The "most interesting" finding was the pancreatic cyst, because, at this size and location, there's a 3 percent chance it will become cancerous in the next five years. But if annual follow-up scans of my pancreas (covered by insurance) show it's getting bigger, the cyst can be removed before it becomes cancer. For me, this made the MRI worthwhile. Sure, there was a 97 percent likelihood the cyst never would develop into a problem even if I hadn't learned about it. But now, with minimal inconvenience, I can eliminate that 3 percent risk of getting pancreatic cancer, the most lethal of major malignancies.

Read more of this story at Slashdot.

Despite predictions that AI would replace radiologists, healthcare systems worldwide are hiring more of them because AI tools enhance their work, create new oversight tasks, and increase imaging volumes rather than reducing workloads. "Put all that together with the context of an aging population and growing demand for imaging of all kinds, and you can see why Offiah and the Royal College of Radiologists are concerned about a shortage of radiologists, not their displacement," writes Financial Times authors John Burn-Murdoch and Sarah O'Connor. Amaka Offiah, who is a consultant pediatric radiologist and a professor in pediatric musculoskeletal imaging at the University of Sheffield in the UK, makes a prediction of her own: "AI will assist radiologists, but will not replace them. I could even dare to say: will never replace them." From the report: [A]lmost all of the AI tools in use by healthcare providers today are being used by radiologists, not instead of them. The tools keep getting better, and now match or outperform experienced radiologists even after factoring in false positives or negatives, but the fact that both human and AI remain fallible means it makes far more sense to pair them up than for one to replace the other. Two pairs of eyes can come to a quicker and more accurate judgment, one spotting or correcting something the other missed. And in high-stakes settings where the costs of a mistake can be astronomical, the downside risk from an error by a fully autonomous AI radiologist is huge. "I find this a fascinating demonstration of why even if AI really can do some of the most high-value parts of someone's job, it doesn't mean displacement (even of those few tasks let alone the job as a whole) is inevitable," concludes John. "Though I also can't help noticing a parallel to driverless cars, which were simply too risky to ever go fully autonomous until they weren't." Sarah added: "I think the story of radiologists should be a reminder to technologists not to make sweeping assertions about the future of professions they don't intimately understand. If we had indeed stopped training radiologists in 2016, we'd be in a real mess today."

Read more of this story at Slashdot.

Bruce66423 shares a report from the Los Angeles Times: Tattoo ink doesn't just sit inertly in the skin. New research shows it moves rapidly into the lymphatic system, where it can persist for months, kill immune cells, and even disrupt how the body responds to vaccines. Scientists in Switzerland used a mouse model to trace what happens after tattooing. Pigments drained into nearby lymph nodes within minutes and continued to accumulate for two months, triggering immune-cell death and sustained inflammation. The ink also weakened the antibody response to Pfizer Inc. and BioNTech SE's COVID vaccine when the shot was administered in tattooed skin. In contrast, the same inflammation appeared to boost responses to an inactivated flu vaccine. "This work represents the most extensive study to date regarding the effect of tattoo ink on the immune response and raises serious health concerns associated with the tattooing practice," the researchers said. "Our work underscores the need for further research to inform public health policies and regulatory frameworks regarding the safety of tattoo inks." The findings have been published in the journal Proceedings of the National Academy of Sciences.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the New York Times: The San Francisco city attorney filed on Tuesday the nation's first government lawsuit against food manufacturers over ultraprocessed fare (source may be paywalled; alternative source), arguing that cities and counties have been burdened with the costs of treating diseases that stem from the companies' products. David Chiu, the city attorney, sued 10 corporations that make some of the country's most popular food and drinks. Ultraprocessed products now comprise 70 percent of the American food supply and fill grocery store shelves with a kaleidoscope of colorful packages. Think Slim Jim meat sticks and Cool Ranch Doritos. But also aisles of breads, sauces and granola bars marketed as natural or healthy. It is a rare issue on which the liberal leaders in San Francisco City Hall are fully aligned with the Trump administration, which has targeted ultraprocessed foods as part of its Make America Healthy Again mantra. Mr. Chiu's lawsuit, which was filed in San Francisco Superior Court on behalf of the State of California, seeks unspecified damages for the costs that local governments bear for treating residents whose health has been harmed by ultraprocessed food. The city accuses the companies of "unfair and deceptive acts" in how they market and sell their foods, arguing that such practices violate the state's Unfair Competition Law and public nuisance statute. The city also argues the companies knew that their food made people sick but sold it anyway.

Read more of this story at Slashdot.

Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer's -- despite initial hopes that it might help against dementia. From a report: Researchers began two large trials involving more than 3,800 people after reports the medicine was having an impact in the real world. But the studies showed the GLP-1 drug, which is already used to manage type 2 diabetes and obesity, made no difference compared to a dummy drug. The disappointing results are due to be presented at an Alzheimer's disease conference next month and are yet to be published in a peer-reviewed journal.

Read more of this story at Slashdot.

A Centers for Disease Control and Prevention webpage that previously made the case that vaccines don't cause autism now says they might. WSJ: The contents of the webpage came up during Health Secretary Robert F. Kennedy Jr. Senate confirmation process. Sen. Bill Cassidy (R., La.) in February said Kennedy had assured him that, if he was confirmed, the CDC would "not remove statements on their website pointing out that vaccines do not cause autism." The revised webpage says: "The claim 'vaccines do not cause autism' is not an evidence-based claim because studies have not ruled out the possibility that infant vaccines cause autism. Studies supporting a link have been ignored by health authorities." The new text posted Wednesday also notes that the Department of Health and Human Services has launched "a comprehensive assessment" to probe the causes of autism.

Read more of this story at Slashdot.

A new treatment for tuberculosis could boost cure rates and shorten the time needed to treat the disease by months, trial results suggest. The Guardian: Globally, an estimated 10.7 million people fell ill with TB last year and 1.23 million died from it. In its annual report on tuberculosis, launched last week, the World Health Organization said it remained a "major global public-health problem" and the leading infectious cause of death. [...] Sorfequiline, a new antibiotic, showed stronger action against the deadly bacteria than existing treatments, with a comparable safety profile, researchers from the TB Alliance told the Union Conference on Lung Health in Copenhagen on Wednesday. The trial involved 309 people across 22 sites in South Africa, the Philippines, Georgia, Tanzania and Uganda, with different dose regimens. All participants had "drug-sensitive" tuberculosis, meaning a standard cocktail of drugs can safely treat them but researchers believe TB infections that are resistant to standard treatment could also be helped. The trial suggested a sorfequiline-based regimen could be used for anyone testing positive, said Dr Maria Beumont, vice-president of TB Alliance.

Read more of this story at Slashdot.

An anonymous reader shares a report: Federal health officials have linked two massive US measles outbreaks, confirming that the country is about two months away from losing its measles elimination status, according to a report by The New York Times. The Times obtained a recording of a call during which officials from the Centers for Disease Control and Prevention confirmed to state health departments that the ongoing measles outbreak at the border of Arizona and Utah is a continuation of the explosive outbreak in West Texas that began in mid- to late-January. That is, the two massive outbreaks are being caused by the same subtype of measles virus. This is a significant link that hasn't previously been reported despite persistent questions from journalists and concerns from health experts, particularly in light of Canada losing its elimination status last week. The loss of an elimination status means that measles will once again be considered endemic to the US, an embarrassing public health backslide for a vaccine-preventable disease.

Read more of this story at Slashdot.

An anonymous reader shared this report from the Guardian: The number of deaths linked to superbugs that do not respond to frontline antibiotics increased by 17% in England last year, according to official figures that raise concerns about the ongoing increase in antimicrobial resistance. The figures, released by the UK Health Security Agency, also revealed a large rise in private prescriptions for antibiotics, with 22% dispensed through the private sector in 2024. The increase in private prescribing is partly explained by the Pharmacy First scheme, a flagship policy of Rishi Sunak's government that allows patients to be prescribed antibiotics for common illnesses without seeing a GP, raising questions about whether the shift in prescribing patterns risks contributing to the rise in resistance. "Antibiotic resistance is one of the greatest health threats we face," said the UKHSA's chief executive, Prof Susan Hopkins. "More people than ever are acquiring infections that cannot be effectively treated by antibiotics. This puts them at greater risk of serious illness and even death, with our poorest communities hit the hardest... It's positive that we've seen antibiotic use fall in England within the NHS but we need to go further, faster," said Hopkins. "Please remember to only take antibiotics if you have been told to do so by a healthcare professional. Do not save some for later or share them with friends and family. If you have leftover antibiotics, please bring them to a pharmacy for appropriate disposal."

Read more of this story at Slashdot.

After more than a decade of planning, the launch of the African Medicines Agency (AMA) is being celebrated in Mombasa, Kenya, this week at the Seventh Biennial Scientific Conference on Medical Products Regulation in Africa. From a report: The agency's establishment marks a pivotal moment in Africa's public health, at a time when the need for biomedical research conducted in Africa, focused on African health problems, has never been greater. Africa holds higher levels of human genetic diversity than anywhere else on Earth, but this diversity has not been adequately studied. And many globally approved treatments and vaccines for diseases such as HIV/AIDS, malaria and tuberculosis are less effective, and can even be harmful in some people of African ancestry. This year, cuts of billions of US dollars in international funding for biomedical research and health services in Africa have left millions of people without access to life-saving treatments or, in the case of researchers and health-care workers, unemployed. This demonstrates the immense vulnerability that comes with relying on funding from external donors. What's more, Africa's phenomenal population growth and pace of urbanization is bringing fresh challenges -- as well as opportunities -- around health and disease. In Africa's cities today, the inhabitants of increasingly affluent neighbourhoods are demanding high-quality medicines and health care. But in low-income areas, high population density, inadequate housing and poor sanitation are facilitating the spread of respiratory and diarrhoeal infections. And everywhere, inadequate diets, air pollution, smoking and physical inactivity are driving increased rates of cardiovascular disease, diabetes and cancer. By 2100, Africa is expected to host 13 of the world's 20 largest cities, and such inequalities are likely to worsen.

Read more of this story at Slashdot.